

<b>Name of the Issue: Akums Drugs and Pharmaceuticals Limited</b>	
<b>1 Type of Issue</b>	Initial Public Offer
<b>2 Issue Size (Rs. Mn)</b>	18567.37*
<i>*Source: Prospectus dated August 1, 2024</i>	
<b>3 Grade of issue along with name of the rating agency</b>	
<b>Name</b>	NA
<b>Grade</b>	NA

<b>4 Subscription Level (Number of times)</b>	64.64*
<i>* excluding Anchor Investor Portion and after removing multiple and duplicate bids</i>	
<i>Source: Minutes for basis of allotment dated August 2, 2024</i>	

<b>5 QIB Holding (as a %age of Outstanding Capital) as disclosed to the stock exchanges</b>	
<b>Particulars</b>	<b>%</b>
(i) On Allotment **	12.92
(ii) at the end of the 1st Quarter immediately after the listing of the issue (September 30, 2024) *	Not Available
(iii) at the end of 1st FY (March 31, 2025)*	Not Available
(iv) at the end of 2nd FY (March 31, 2026) *	Not Available
(v) at the end of 3rd FY (March 31, 2027) *	Not Available

*\*\*Basis of Allotment (excluding pre-issue QIB holding)*

*\* QIB Holding not disclosed as reporting for relevant period has not been completed.*

<b>6 Financials of the issuer</b>			
<b>Parameters</b>	<b>1st FY (March 31,2025)*</b>	<b>2nd FY (March 31,2026)*</b>	<b>3rd FY (March 31,2027)*</b>
Income from operations	Not Available	Not Available	Not Available
Net Profit/(Loss) for the period	Not Available	Not Available	Not Available
Paid-up equity share capital	Not Available	Not Available	Not Available
Reserves excluding revaluation reserves	Not Available	Not Available	Not Available

*\* Financials not available as reporting for the relevant years has not been completed.*

<b>7 Trading Status</b>	
The equity shares of Mankind Pharma Limited are listed on both the BSE Limited ("BSE") and the National Stock Exchange of India Limited ("NSE") (and together with BSE the "Stock Exchanges")	
The equity shares have not been suspended or delisted.	

<b>Particulars</b>	<b>Status</b>
(i) at the end of 1st FY (March 31, 2025)*	Not Available
(ii) at the end of 2nd FY (March 31, 2026)*	Not Available
(iii) at the end of 3rd FY (March 31, 2027)*	Not Available

*\* Trading status not disclosed as the relevant fiscal years have not been completed.*

<b>8 Change in Directors of Issuer from the disclosures in the offer document</b>							
Particulars	Name of Director	Appointed / Resigned					
(i) at the end of 1st FY (March 31, 2025)*	Not Available	Not Applicable					
(ii) at the end of 2nd FY (March 31, 2026)*	Not Available	Not Available					
(iii) at the end of 3rd FY (March 31, 2027)*	Not Available	Not Available					
<i>* Changes in Directors of Issuer not updated as the relevant financial years have not been completed</i>							
<b>9 Status of implementation of project/ commencement of commercial production</b>							
(i) as disclosed in the offer document	Not applicable						
(ii) Actual implementation	Not applicable						
(iii) Reasons for delay in implementation, if any	Not applicable						
<b>10 Status of utilization of issue proceeds</b>							
(i) as disclosed in the offer document			6,373.70				
(ii) Actual implementation			To be updated				
(iii) Reasons for delay in implementation, if any			To be updated				
<b>11 Comments of monitoring agency, if applicable</b>							
(i) Comments on use of funds					Not applicable		
(ii) Comments on deviations, if any, in the use of proceeds of the Issue from the objects stated in the Offer document					Not applicable		
(iii) Any other reservations expressed by the monitoring agency about the end use of funds					Not applicable		
<b>12 Pricing Data</b>							
Designated Stock Exchange	NSE						
Issue Price (Rs.)	679.00						
Listing Date	August 06, 2024						
Price parameters	At close of listing day August 06, 2024	Close of 30th calendar day from listing day	Close of 90th calendar day from listing day	As at the end of the 1st FY after the listing of the issue (31st March,2025) <sup>(1)</sup>			
				Closing price	High	Low	
Market Price	679.00	Not Available	Not Available	Not Available	Not Available	Not Available	
Nifty 50*	23,992.55	Not Available	Not Available	Not Available	Not Available	Not Available	
Price parameters	As at the end of the 2nd FY after the listing of the issue (31st March,2026) <sup>(1)</sup>			As at the end of the 3rd FY after the listing of the issue (31st March,2027) <sup>(1)</sup>			
	Closing price	High	Low	Closing price	High	Low	
Market Price	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	
Nifty 50*	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	

\* Being index of NSE, the designated stock exchange

(1) The pricing data is not disclosed as the relevant fiscal years have not been completed

**13 Basis for Issue Price**

Accounting ratio		Face Value per share (Rs.)	As disclosed in offer document*	At the end of 1st FY (March 31,2025)**	At the end of 1st FY (March 31,2026)**	At the end of 1st FY (March 31,2027)**
EPS (Diluted)	<b>Company</b>					
	<i>Consolidated</i>	2	-0.28	Not Available	Not Available	Not Available
	<b>Peer Group:</b>					
	Divi's Laboratories	2	60.27			
	Suven Pharma	1	11.8	Not Available	Not Available	Not Available
	Gland Pharma	1	46.89	Not Available	Not Available	Not Available
	Torrent Pharma	5	48.94	Not Available	Not Available	Not Available
	Alkem Laboratories	2	150.19	Not Available	Not Available	Not Available
	Eris Lifesciences	1	28.79	Not Available	Not Available	Not Available
	JB Chemicals	1	34.85	Not Available	Not Available	Not Available
	Mankind Pharma	1	47.68	Not Available	Not Available	Not Available
	Innova Captab	10	18.66	Not Available	Not Available	Not Available
	<b>Industry Avg</b>		49.79	Not Available	Not Available	Not Available
	P/E	<b>Company</b>				
<i>Consolidated</i>		2	NA	Not Available	Not Available	Not Available
<b>Peer Group:</b>						
Divi's Laboratories		2	74.99	Not Available	Not Available	Not Available
Suven Pharma		1	69.54	Not Available	Not Available	Not Available
Gland Pharma		1	42.45	Not Available	Not Available	Not Available
Torrent Pharma		5	60.2	Not Available	Not Available	Not Available
Alkem Laboratories		2	34.18	Not Available	Not Available	Not Available
Eris Lifesciences		1	34.95	Not Available	Not Available	Not Available
JB Chemicals		1	51.38	Not Available	Not Available	Not Available
Mankind Pharma		1	44.65	Not Available	Not Available	Not Available
Innova Captab		10	29.91	Not Available	Not Available	Not Available
<b>Industry Avg</b>			49.14	Not Available	Not Available	Not Available

RoNW	<b>Company</b>					
	<b>Consolidated</b>	2	-0.57%	Not Available	Not Available	Not Available
	<b>Peer Group:</b>					
	Divi's Laboratories	2	11.79%	Not Available	Not Available	Not Available
	Suven Pharma	1	14.64%	Not Available	Not Available	Not Available
	Gland Pharma	1	8.85%	Not Available	Not Available	Not Available
	Torrent Pharma	5	24.15%	Not Available	Not Available	Not Available
	Alkem Laboratories	2	17.41%	Not Available	Not Available	Not Available
	Eris Lifesciences	1	15.16%	Not Available	Not Available	Not Available
	JB Chemicals	1	18.90%	Not Available	Not Available	Not Available
	Mankind Pharma	1	20.43%	Not Available	Not Available	Not Available
	Innova Captab	10	11.35%	Not Available	Not Available	Not Available
	<b>Industry Avg</b>		15.85%	Not Available	Not Available	Not Available
NAV per share	<b>Company</b>					
	<b>Consolidated</b>	2	49.59	Not Available	Not Available	Not Available
	<b>Peer Group:</b>					
	Divi's Laboratories	2	511.21	Not Available	Not Available	Not Available
	Suven Pharma	1	80.56	Not Available	Not Available	Not Available
	Gland Pharma	1	529.65	Not Available	Not Available	Not Available
	Torrent Pharma	5	202.57	Not Available	Not Available	Not Available
	Alkem Laboratories	2	862.46	Not Available	Not Available	Not Available
	Eris Lifesciences	1	190.12	Not Available	Not Available	Not Available
	JB Chemicals	1	188.37	Not Available	Not Available	Not Available
	Mankind Pharma	1	233.73	Not Available	Not Available	Not Available
	Innova Captab	10	145.2	Not Available	Not Available	Not Available
	<b>Industry Avg</b>		327.10	Not Available	Not Available	Not Available

Notes

\* Sourced from Prospectus dated August 01, 2024.

\*\*Not available as the relevant fiscal years have not been completed / information not disclosed

#### 14 Any other material information

Particulars	Date	Remarks
Not Applicable		

Source: Stock Exchange websites i.e. www.bseindia.com and www.nseindia.com